Aktie A3C4Y0 ABBISKO CAYMAN LIMITED
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Abbisko Cayman Limited

Aktien

A3C4Y0

KYG0028A1085

2256

Verzögert Hong Kong S.E.
Andere Börsenplätze
 05:52:57 02.07.2024 		% 5 Tage % 1. Jan.
3,25 HKD 0,00 % Intraday Chart für Abbisko Cayman Limited -3,85 % -10,96 %
28.06. Abbisko Therapeutics Co., Ltd. präsentiert neue klinische Phase-II-Daten seines hochselektiven FGFR4-Hemmers Irpagratinib (ABSK011) in Kombination mit Atezolizumab für den Esmo-Gi-Kongress 2024 CI
18.06. Abbisko Cayman Limited (SEHK:2256) beginnt im Rahmen der am 18. Juni 2024 erteilten Ermächtigung mit dem Rückkauf von 70.219.935 Aktien, was 10% des ausgegebenen Aktienkapitals entspricht. CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
50% ORR: Impressive Clinical Trial Data for Irpagratinib Combined with Atezolizumab in Advanced Hepatocellular Carcinoma Stuns ESMO-GI Congress
Abbisko Therapeutics Co., Ltd. Presents New Phase II Clinical Data of Its Highly Selective FGFR4 Inhibitor Irpagratinib in Combination with Atezolizumab for the 2024 Esmo-Gi Congress
Abbisko Cayman Limited commences an Equity Buyback for 70,219,935 shares, representing 10% of its issued share capital, under the authorization approved on June 18, 2024.
Abbisko Cayman Limited's Equity Buyback announced on March 13, 2024, has expired.
Abbisko Cayman Unit's Cancer Drug To Be Clinically Tested in Combination with Shanghai Allist's Furmonertinib
Abbisko Cayman Limited Appoints Yu Hongping as Joint Company Secretaries
Abbisko Cayman's Liver Cancer Drug Gets US FDA Orphan Drug Designation
Abbisko Cayman Limited Voluntary Announcement FGFR4 Inhibitor Irpagratinib Granted Odd by FDA
Abbisko Cayman Limited Announces Resignation of Tian Huimin as Joint Company Secretary
Abbisko Cayman's Unit Presents Pre-Clinical Study of Liver Cancer Drug at AACR Annual Meeting
Abbisko Cayman Completes Patient Enrollment for Phase 3 Trial of Joint Tumor Treatment
Abbisko Therapeutics Co., Ltd. Completes All Patient Enrollment for the Global Phase III TGCT Trial of Its CSF-1R Inhibitor - Pimicotinib
Abbisko Cayman's Attributable Loss Narrows as Revenue, Other Gains Rise
Abbisko Cayman to Buy Back, Cancel Up to HK$100 Million Shares
Abbisko Cayman Limited commences an Equity Buyback for 70,219,935 shares, representing 10% of its issued share capital, under the authorization approved on June 14, 2023.
Abbisko Cayman Limited Reports Earnings Results for the Full Year Ended December 31, 2023
Abbisko Cayman Completes Dosing for Phase 1 Trials for Lung Cancer Treatment
Abbisko Cayman Receives $70 Million Upfront Payment for Licensing of Tumor Treatment
Abbisko Cayman Trustee Buys 6.1 Million Shares Under Restricted Share Scheme
European Medicines Agency Grants Orphan Drug Designation to Abbisko's Tumor Drug
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3C4Y0 Aktie
  4. Nachrichten Abbisko Cayman Limited
  5. Andere Sprachen